Platinum Priority – Brief CorrespondenceEditorial by Alexander P. Cole, Firas Abdollah and Quoc-Dien Trinh on pp. 231–232 of this issueOverall Survival in Patients with Localized Prostate Cancer in the US Veterans Health Administration: Is PIVOT Generalizable?
References (20)
- et al.
Sociodemographic and clinical risk characteristics of patients with prostate cancer within the Veterans Affairs health care system: data from CaPSURE
J Urol
(2003) Managing localized prostate cancer in the era of prostate-specific antigen screening
Cancer
(2013)- et al.
Overdiagnosis in cancer
J Nat Cancer Inst
(2010) - et al.
Radical prostatectomy versus observation for localized prostate cancer
N Engl J Med
(2012) - NCCN clinical practice guidelines in oncology (NCCN Guidelines): prostate cancer, V.1.2011. National Comprehensive...
- National Center for Veterans Analysis and Statistics. US Department of Veterans Affairs Web site....
- et al.
Cancer incidence among patients of the U.S. Veterans Affairs Health Care System
Mil Med
(2012) - et al.
The health status of elderly veteran enrollees in the Veterans Health Administration
J Am Geriatr Soc
(2004) - et al.
Comparing the health status of VA and non-VA ambulatory patients: the veterans’ health and medical outcomes studies
J Ambul Care Manage
(2004) - et al.
Patient-reported measures of health: the Veterans Health Study
J Ambul Care Manage
(2004)
Cited by (18)
Life expectancy estimates for patients diagnosed with prostate cancer in the Veterans Health Administration
2020, Urologic Oncology: Seminars and Original InvestigationsCitation Excerpt :Additionally, existing life expectancy estimates may not be used if they are not transportable to a specific population. The poor survival of participants in the PIVOT trial (primarily drawn from the VHA) underscores the need for tools to generate VHA-specific life expectancy estimates [8,9]. We set out to develop life expectancy estimates for Veterans with prostate cancer treated within the VHA, the largest national integrated health care system in the United States.
Real-world practice patterns in veterans with metastatic castration-resistant prostate cancer
2020, Urologic Oncology: Seminars and Original InvestigationsCitation Excerpt :mCRPC is incurable, with most patients surviving less than 3 years [3,5,11–14]. Prostate cancer is the most commonly diagnosed nonskin cancer among patients cared for and treated in the Veterans Health Administration (VHA) [15]. As the largest integrated healthcare system in the United States, the VHA serves 6-8.5 million Veterans of the US Armed Forces each year at over 1,700 clinics and 152 hospitals, with approximately 13 million primary care visits annually [16].
The Research Implications of Prostate Specific Antigen Registry Errors: Data from the Veterans Health Administration
2018, Journal of UrologyCitation Excerpt :For each scenario we compared the registry derived cohort to the laboratory derived cohort. We determined the age, gender, race/ethnicity and primary treatment of each patient using administrative data stored in the VHA CDA (Corporate Data Warehouse).6 We calculated the Chamberlain percent positive agreement of the cohorts constructed with registry PSA values compared with laboratory file PSA values.7
Re: Follow-up of Prostatectomy Versus Observation for Early Prostate Cancer
2018, European Urology